Immuneering/IMRX

$1.63

-5.21%
-
1D1W1MYTD1YMAX

About Immuneering

Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the MAPK pathway. The Company’s second product candidate, IMM-6-415, aims to achieve universal-MAPK activity with an accelerated twice-daily oral dosing cadence, also through deep cyclic inhibition of the MAPK pathway. IMM-6-415 is in Investigational New Drug application (IND), enabling studies. Its pipeline also includes Trifecta MEK, RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.

Ticker

IMRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Benjamin Zeskind

Employees

68

Headquarters

Cambridge, United States

Immuneering Metrics

BasicAdvanced
$52.71M
Market cap
-
P/E ratio
-$1.89
EPS
-
Beta
-
Dividend rate
$52.71M
$12.23
$1.56
681.3K
11.355
-47.54%
-53.36%
-51.16%
0.582
0.631
-100%
1.51%

What the Analysts think about Immuneering

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 7 analysts.
715.34% upside
High $25.00
Low $3.00
$1.63
Current price
$13.29
Average price target

Immuneering Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-15M
20%
Profit margin
0%
-

Immuneering Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 11.27%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.51
-$0.43
-$0.43
-$0.52
-
Expected
-$0.56
-$0.53
-$0.49
-$0.47
-$0.50
Surprise
-8.93%
-18.48%
-12.91%
11.27%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Immuneering stock?

Immuneering (IMRX) has a market cap of $52.71M as of April 24, 2024.

What is the P/E ratio for Immuneering stock?

The price to earnings (P/E) ratio for Immuneering (IMRX) stock is 0 as of April 24, 2024.

Does Immuneering stock pay dividends?

No, Immuneering (IMRX) stock does not pay dividends to its shareholders as of April 24, 2024.

When is the next Immuneering dividend payment date?

Immuneering (IMRX) stock does not pay dividends to its shareholders.

What is the beta indicator for Immuneering?

Immuneering (IMRX) does not currently have a Beta indicator.

What is the Immuneering stock price target?

The target price for Immuneering (IMRX) stock is $13.29, which is 715.34% above the current price of $1.63. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Immuneering stock

Buy or sell Immuneering stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing